文献速递乳腺癌放疗

早期乳腺癌保乳术后辅助抗雌激素治疗与放疗的自付费用模型:Medicaid与Medicare计划分析

Out-of-Pocket Cost Modeling of Adjuvant Antiestrogen and Radiation Therapy After Lumpectomy for Early-Stage Breast Cancer Across Medicaid and Medicare Plans.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-03-01

该研究基于公开保险数据构建财务估算模型,估算≥70岁、淋巴结阴性、早期雌激素受体阳性乳腺癌患者在Medicaid、Original Medicare、Medigap Plan G和Medicare Part D Rx计划下接受5年抗雌激素治疗(ET)和/或5次或15次放疗的自付费用。结果显示Original Medicare受益人ET联合15次放疗自付费用最高($3713.92),Medicaid受益人经批准的治疗无自付费用。模型旨在提高治疗费用透明度,帮助患者根据个人偏好做出治疗决策。

要点

  • Original Medicare受益人ET联合15次放疗自付费用最高,为$3713.92。
  • Medicaid受益人经批准的治疗选项均无自付费用。
  • 模型基于公开保险数据而非理赔数据,旨在提高费用透明度。

核心结论

  • 该模型基于各保险计划的实际费用估算而非理赔数据,通过估算Medicare和Medicaid计划内的费用,为患者费用提供了一定程度的透明度。
  • 了解患者自身承担的费用后,可能进一步促进患者根据个人优先事项和偏好做出治疗决策。

研究设计与样本

  • 财务估算模型,使用公开保险数据中计划特定的福利覆盖材料,以5年时间范围为界进行估算。
  • 模型假设患者为≥70岁、淋巴结阴性、早期雌激素受体阳性乳腺癌、符合Medicare和/或Medicaid资格。
  • 放疗方案采用5次和15次放疗(依据美国国家综合癌症网络指南认可的方案),ET处方持续5年。
  • 自付费用总额由治疗费用、免赔额和共付额/共同保险相加确定,基于Medicaid、Original Medicare、Medigap Plan G和Medicare Part D Rx计划。

主要发现

  • Original Medicare受益人ET单独自付总额为$2738.52,5次放疗单独为$2221.26,15次放疗单独为$2573.92,ET联合5次放疗为$3361.26,ET联合15次放疗为$3713.92。
  • Medigap Plan G受益人放疗单独自付费用为$1130.00,ET单独和ET联合放疗自付费用均为$2270.00。
  • Medicaid受益人所有经Medicaid批准的治疗均无限制覆盖,两种辅助治疗选项均无自付费用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimal adjuvant therapy (antiestrogen therapy [ET] + radiation therapy or ET alone, or in some reports radiation therapy alone) in older women with early-stage breast cancer has been highly debated. However, granular details on the role of insurance in the out-of-pocket cost for patients receiving ET with or without radiation therapy are lacking. This project disaggregates out-of-pocket costs by insurance plans to increase treatment cost transparency. METHODS AND MATERIALS: Several radiation therapy schedules are accepted standards as per the National Comprehensive Cancer Network guidelines. For our financial estimate model, we used the 5-fraction and 15-fraction radiation therapy and ET prescribed over a 5-year duration. The total aggregate out-of-pocket costs were determined from the sum of treatment costs, deductibles, and copays/coinsurance based on Medicaid, Original Medicare, Medigap Plan G, and Medicare Part D Rx plans. The model assumes a Medicare- and/or Medicaid-eligible patient ≥70 years of age with node-negative, early-stage estrogen-receptor-positive breast cancer. Patient out-of-pocket costs were estimated from publicly available insurance data from plan-specific benefit coverage materials using a 5-year time horizon. RESULTS: Original Medicare beneficiaries face a total out-of-pocket treatment charge of $2738.52 for ET alone, $2221.26 for 5-fraction radiation therapy alone, $2573.92 for 15-fraction radiation therapy alone, $3361.26 for combined ET+ 5-fraction radiation therapy, and $3713.92 for combined ET + 15-fraction radiation therapy. Medigap Plan G beneficiaries have an out-of-pocket charge of $1130.00 with radiation therapy alone and face an out-of-pocket of $2270.00 for ET alone and combined ET+ radiation therapy. For Medicaid beneficiaries, all treatments approved by Medicaid are covered without limit, resulting in no out-of-pocket expense for either adjuvant treatment option. CONCLUSIONS: This model (based on actual cost estimates per insurance plan rather than claims data), by estimating expenses within Medicare and Medicaid plans, provides a level of transparency to patient cost. With knowledge of the costs borne by patients themselves, treatment decisions informed by patients' individual priorities and preferences may be further enhanced.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Wu VS, Khlopin M, Chadha M, et al. Out-of-Pocket Cost Modeling of Adjuvant Antiestrogen and Radiation Therapy After Lumpectomy for Early-Stage Breast Cancer Across Medicaid and Medicare Plans. Int J Radiat Oncol Biol Phys. 2024. PMID: 38432284. doi:10.1016/j.ijrobp.2024.02.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。